Bayer stock holds on to a report-heavy setup
Published on 07/22/2026 at 20:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock (DE000BAY0017) trades on the basis of its latest published report figures and market context, with the company citing 2024 sales of EUR 46.6 billion, EBITDA before special items of EUR 10.1 billion, and free cash flow of EUR 1.5 billion in its annual reporting materials. The company also reported that group sales fell 2.0% year on year in 2024, a comparison that matters more for investors than any short-lived headline move.
EUR 46.6 billion revenue
Bayer's 2024 revenue of EUR 46.6 billion gives the stock a clear operating reference point, while EBITDA before special items of EUR 10.1 billion and free cash flow of EUR 1.5 billion set the financial frame for valuation and balance-sheet discussion. Those figures are more useful than a slogan because they connect sales scale, profit generation, and cash conversion in the same year.
The 2.0% sales decline in 2024 is the key comparison in that set, because it shows where the business still needs improvement even before any new quarterly update arrives. For a large-cap healthcare and crop-science group, that combination of sales pressure and cash generation is usually what shapes the next market read-through.
Profit and cash flow
Profitability matters because Bayer's 2024 EBITDA before special items of EUR 10.1 billion sits alongside free cash flow of EUR 1.5 billion, a gap that highlights how working capital and capital spending can shape the stock reaction to later results. The same annual reporting materials also show that the company's sales base stayed large at EUR 46.6 billion, which keeps small percentage changes meaningful in absolute euro terms.
That mix gives investors a simple interpretation: when revenue is still above EUR 46 billion but sales are down 2.0%, the market watches whether the next reporting period improves the trend or merely stabilizes it. The cash figure is the other anchor, because EUR 1.5 billion in free cash flow is enough to keep the balance-sheet discussion in view without turning the story into a pure earnings surprise play.
What the numbers say
The operating picture is not a single-line story. It combines EUR 46.6 billion of sales, EUR 10.1 billion of EBITDA before special items, EUR 1.5 billion of free cash flow, and a 2.0% year-on-year decline in group sales, all of which come from the latest reporting context and together define the stock's current evidence base.
For market readers, the most useful comparison is the year-on-year sales move, because it gives a concrete delta rather than a general description. A 2.0% decline is modest in percentage terms but meaningful at Bayer's revenue scale, where each point still represents hundreds of millions of euros.
Crop science matters
Bayer's Crop Science business remains central to the equity story because it is one of the company's major operating pillars and a large contributor to the group revenue mix. The segment matters particularly when agricultural pricing, herbicide demand, and planting conditions feed through to group sales and margin trends.
That makes the segment more than a background detail. In a company with EUR 46.6 billion of annual sales, investors tend to focus on whether Crop Science offsets pressure elsewhere or adds to it, especially when the group is still working through a 2.0% sales decline.
Stock level backdrop
Bayer stock is therefore best read against its latest annual numbers rather than a one-day narrative. The euro figures are the clearest guide, because they define the scale of the business and the pressure points that may matter in the next update cycle.
As a market-value reference, the stock remains tied to a company that generated EUR 46.6 billion of revenue in 2024 and EUR 1.5 billion of free cash flow in the same period, while sales fell 2.0% year on year. That is the factual backdrop behind the share price story.
Crop science products
Within the group, Crop Science is the representative product and business line to watch because it connects farm inputs, seasonal demand, and pricing power directly to the company-wide numbers. The segment is relevant whenever investors look for evidence that group revenue can stabilize after a year of lower sales.
Its importance is practical rather than theoretical: a business line tied to agricultural cycles can help explain why a large group can still report EUR 46.6 billion in sales while also posting a 2.0% annual decline. That is the type of operating detail that often matters more than headline noise.
Closing level
Bayer stock is trading against a 2024 framework of EUR 46.6 billion in sales, EUR 10.1 billion in EBITDA before special items, and EUR 1.5 billion in free cash flow, with group sales down 2.0% year on year. Those are the numbers that define the current setup and the next reporting comparison.
Bayer snapshot
- Company: Bayer AG
- ISIN: DE000BAY0017
- Ticker: XETRA: BAYN
- Trading venue: Xetra
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: DAX
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
